Mya Thomae, Harjit Kullar

Jun 09, 2015

Transgenomic has elected Mya Thomae to its board of directors. She is currently vice president of regulatory affairs at Illumina. Before that, she served as CEO of Myraqa, a diagnostics regulatory consulting firm, which was acquired by Illumina in 2014.

Transgenomic has also appointed Harjit Kullar vice president of marketing for biomarker discovery and genetic assays and platforms. He previously was content marketing leader for cross-functional global digital and web-based initiatives at Bio-Rad. Before that, he was director of product marketing, genomics, at Thermo Fisher Scientific.

Mya Thomae, Harjit Kullar

WHO Approves Abbott Molecular Mpox Assay

Foresight Diagnostics Responds to Roche Lawsuit, Says Claims Asserted in Bad Faith

Participant Health Privacy at Risk From Single-Cell RNA Sequencing Data, Study Suggests

With $40M in Funding, Cancer AI Alliance Aims to Pool Data, Computing Resources to Boost Research

Oncocyte Nets $10.2M in Private Placement, Notes New Customers for Transplant Test